SYMLIN® (pramlintide acetate) injection is indicated as an adjunct treatment for patients with type 2 or type 1 diabetes who use mealtime insulin and have not achieved desired glucose control despite optimal insulin therapy (with or without a concurrent sulfonylurea agent and/or metformin in type 2 diabetes). Go to www.SYMLIN.com/hcp for complete prescribing and safety information, including the Boxed Warning regarding insulin-induced severe hypoglycemia.